SALT SUBSTITUTES FROM A PHARMACEUTICAL POINT OF VIEW

被引：0
|
作者：
PICH, CH
MOEST, T
机构：
来源：
AKTUELLE ERNAHRUNGSMEDIZIN | 1981年 / 6卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：127 / 130
页数：4
相关论文
共 50 条
  • [31] The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
    Arpinelli, Fabio
    Bamfi, Francesco
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
  • [32] FROM THIS POINT OF VIEW
    WILLIAMS, J
    ARTSCANADA, 1978, (218-): : 56 - 57
  • [33] Marine Toxins as Pharmaceutical Treasure Troves: A Focus on Saxitoxin Derivatives from a Computational Point of View
    Flores-Holguin, Norma
    Salas-Leiva, Joan S.
    Nunez-Vazquez, Erick J.
    Tovar-Ramirez, Dariel
    Glossman-Mitnik, Daniel
    MOLECULES, 2024, 29 (01):
  • [34] Differences in the interpretation of the GLP requirements by OECD monitoring authorities: the point of view from the pharmaceutical industry
    Lowing, Raymond K.
    ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2008, 44 (04): : 395 - 402
  • [35] Clinical drug research in Germany - Problems and chances - from the pharmaceutical industry's point of view
    Weihrauch, TR
    Baumbauer, E
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (11): : 1047 - 1050
  • [36] Pharmaceutical excipients - The view from the EU
    Pharm. Technol., 2008, 4 (84-85):
  • [37] Dietary Sodium- and Potassium-Enriched Salt Substitutes-The Tipping Point?
    Jones, Daniel W.
    Egan, Brent M.
    Lackland, Daniel Thomas
    JAMA CARDIOLOGY, 2025,
  • [38] CFC substitutes (R600a and R134a): performance, manufacturing, and costs from the compressor point of view
    Biscaldi, E
    ECO-REFRIGERATION, 1997, : 61 - 72
  • [39] CONSEQUENCES OF PATENTABILITY ON PHARMACEUTICAL-INDUSTRY - THE POINT OF VIEW OF A PATENT ATTORNEY
    BIANCHETTI, G
    CHIMICA & L INDUSTRIA, 1982, 64 (7-8): : 501 - 505
  • [40] Recent Developments in European Pharmaceutical Law 2004: A Legal Point of View
    Markus Hartmann
    Florence Hartmann-Vareilles
    Drug information journal : DIJ / Drug Information Association, 2005, 39 : 193 - 207
12345